Kama Ausborn
Psychiatric/Mental Health · Waterloo, IANPI 1669056123
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $47,690 of the $63,545 with a category attached, or 75.0%. Alkermes, Inc. accounts for 92.6% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2023 at $33,012 and has fallen 67.5% since, to $10,728 in 2025. Among psychiatric/mental health clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 546 payments — averaging $116.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$59K
- AbbVie$846
- Neurocrine Biosciences, Inc.$707
- Johnson & Johnson$671
- Otsuka America Pharmaceutical, Inc.$438
- Axsome Therapeutics, Inc.$326
- plus $2K from 20 others
What the payments were for
- Consulting fees$3,7106%
- Speaking & faculty fees$47,69075%
- Travel & lodging$4,4477%
- Food & beverage$7,65012%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 146 | $58,813 |
| AbbVie | 68 | $846 |
| Neurocrine Biosciences, Inc. | 115 | $707 |
| Johnson & Johnson | 62 | $671 |
| Otsuka America Pharmaceutical, Inc. | 34 | $438 |
| Axsome Therapeutics, Inc. | 20 | $326 |
| Corium, LLC | 22 | $294 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $249 |
| Teva Pharmaceuticals USA, Inc. | 11 | $227 |
| Lundbeck LLC | 8 | $161 |
| Sunovion Pharmaceuticals Inc. | 10 | $153 |
| Indivior Inc. | 6 | $122 |
| Ironshore Pharmaceuticals Inc. | 5 | $85 |
| Supernus Pharmaceuticals, Inc. | 4 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Idorsia Pharmaceuticals US Inc | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $45 |
| Harmony Biosciences LLC | 3 | $38 |
| Merck | 2 | $36 |
| Tris Pharma Inc | 2 | $31 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Itamar Medical Inc | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Almatica Pharma LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$181,221
- ARISTADA$51,115
- ARISTADA INITIO$5,811
- INVEGA SUSTENNA$110
How this compares
$63,545 in reported general payments places this provider in the 95th percentile of 443 psychiatric/mental health providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 117 | $376,916 |
| Invega TrinzaPaliperidone Palmitate | 34 | $337,260 |
| VraylarCariprazine Hcl | 143 | $191,927 |
| AristadaAripiprazole Lauroxil | 59 | $183,390 |
| Abilify MaintenaAripiprazole | 17 | $36,670 |
| RexultiBrexpiprazole | 22 | $35,032 |
| Aripiprazole | 22 | $5,893 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,210 |
| Vilazodone Hcl | 37 | $4,077 |
| Paliperidone ErPaliperidone | 19 | $2,714 |
| Olanzapine | 65 | $1,848 |
| Zaleplon | 32 | $1,434 |
| Atomoxetine Hcl | 15 | $1,236 |
| Clonazepam | 102 | $1,207 |
| Fluphenazine Decanoate | 11 | $1,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $671 | $714,175151 claims |
| AbbVieVraylar | $846 | $191,927143 claims |
| Alkermes, Inc.Aristada | $58,813 | $183,39059 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $438 | $71,70339 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $63 | $4,21011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 443 psychiatric/mental health providers in Iowa.
Other psychiatric/mental health in Waterloo
- Abby KolthoffWaterloo$7K
- Evans KomenWaterloo$7K
- Stephanie GieslerWaterloo$5K
- Emily SwartleyWaterloo$4K
- Tarrah HollidayAtlantic$421K
- Kelsie SwisherParkersburg$235K
- Jennifer BradleyCedar Rapids$66K
- Quentin ChambersDes Moines$40K
- Tenaea JeppesonFort Dodge$38K
- Jennifer WittmanCoralville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.